Saltz LB - Search Results

1

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Chung KY, et al. Among authors: saltz lb. J Clin Oncol. 2005 Mar 20;23(9):1803-10. doi: 10.1200/JCO.2005.08.037. Epub 2005 Jan 27. J Clin Oncol. 2005. PMID: 15677699

2

Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.

Conti JA, Kemeny NE, Saltz LB, André AM, Grossano DD, Bertino JR. Conti JA, et al. Among authors: saltz lb. Cancer. 1995 Feb 1;75(3):769-74. doi: 10.1002/1097-0142(19950201)75:3<769::aid-cncr2820750304>3.0.co;2-5. Cancer. 1995. PMID: 7828126 Clinical Trial.

3

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.

Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C. Conti JA, et al. Among authors: saltz lb. J Clin Oncol. 1996 Mar;14(3):709-15. doi: 10.1200/JCO.1996.14.3.709. J Clin Oncol. 1996. PMID: 8622015

4

Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy.

Tiersten A, Saltz LB. Tiersten A, et al. Among authors: saltz lb. J Clin Oncol. 1996 Jul;14(7):2043-6. doi: 10.1200/JCO.1996.14.7.2043. J Clin Oncol. 1996. PMID: 8683234

5

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.

Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP. Saltz LB, et al. J Clin Oncol. 1996 Nov;14(11):2959-67. doi: 10.1200/JCO.1996.14.11.2959. J Clin Oncol. 1996. PMID: 8918493 Clinical Trial.

6

Adjuvant treatment of colorectal cancer.

Saltz LB, Kelsen DP. Saltz LB, et al. Annu Rev Med. 1997;48:191-202. doi: 10.1146/annurev.med.48.1.191. Annu Rev Med. 1997. PMID: 9046955 Review.

7

9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.

Saltz LB, Kemeny NE, Tong W, Harrison J, Berkery R, Kelsen DP. Saltz LB, et al. Cancer. 1997 Nov 1;80(9):1727-32. doi: 10.1002/(sici)1097-0142(19971101)80:9<1727::aid-cncr5>3.0.co;2-b. Cancer. 1997. PMID: 9351540 Clinical Trial.

8

A phase II study of topotecan administered five times daily in patients with advanced gastric cancer.

Saltz LB, Schwartz GK, Ilson DH, Quan V, Kelsen DP. Saltz LB, et al. Am J Clin Oncol. 1997 Dec;20(6):621-5. doi: 10.1097/00000421-199712000-00018. Am J Clin Oncol. 1997. PMID: 9391553 Clinical Trial.

9

Irinotecan in the first-line treatment of colorectal cancer.

Saltz LB. Saltz LB. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):54-8. Oncology (Williston Park). 1998. PMID: 9726092 Review.

10

Irinotecan and cisplatin in upper gastrointestinal malignancies.

Enzinger PC, Ilson DH, Saltz LB, O'Reilly EM, Kelsen DP. Enzinger PC, et al. Among authors: saltz lb. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):110-3. Oncology (Williston Park). 1998. PMID: 9726102 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

423 results

Search Page

Filters